Advances in extraction, purification, and pharmacological mechanisms of calycosin: a comprehensive review

Abstract

Calycosin, a pivotal isoflavonoid active constituent derived from Astragalus membranaceus, is designated as a key marker compound for the quality assessment of Astragalus and its products in the Pharmacopoeia of the People’s Republic of China (2020 Edition). It exhibits a broad spectrum of pharmacological activities and holds significant potential for clinical application. This article systematically reviews the research progress on calycosin. In terms of extraction, isolation, and purification, techniques such as flash extraction and hydrolytic extraction enable efficient enrichment of the compound, whereas methods such as macroporous adsorption resin and high-speed counter-current chromatography allow for high-purity preparation. The biosynthetic pathways of calycosin encompass the phenylpropanoid pathway in planta, the chemical “one-pot” method in vitro, and synthesisvia microbial cell factories, offering diverse strategies for large-scale production. Structural derivatization, particularly through modification of the 7- and 3'-hydroxyl groups, significantly enhances its solubility and antitumor activity. With respect to pharmacological mechanisms, calycosin exerts multi-pathway and low-toxicity effects in diseases such as inflammation, cancer, and neural injury by modulating multiple signaling pathways, including NF-κB, PI3K/AKT, and MAPK. Furthermore, pharmacokinetic studies indicate that its absorption depends on deglycosylation, that it undergoes substantial hepatic first-pass metabolism, and that its tissue distribution is organ-specific. Safety evaluations suggest low toxicity at therapeutic concentrations. This review aims to clarify the core issues concerning the translation of basic research on calycosin into clinical practice, thereby providing a theoretical foundation for subsequent development.

Keywords

Calycosin / Astragalus membranaceus / Pharmacological activities / Structural derivatization / Biosynthesis

Funding

This work was supported by the Outstanding Doctoral Student Project of Gansu Province (No. 25JRRA258).

Declaration of Competing Interests

The authors declare no conflicts of interests.

References

[1] Chen Z, Liu L, Gao C, et al. Astragali Radix (Huangqi): a promising edible immunomodulatory herbal medicine. J Ethnopharmacol. 2020; 258:112895. https://doi.org/10.1016/j.jep.2020.112895.

[2] Shi Y, Shi X, Zhao M, et al. Pharmacological potential of Astragali Radix for the treatment of kidney diseases. Phytomedicine. 2024; 123:155196. https://doi.org/10.1016/j.phymed.2023.155196.

[3] Yu RY, Zhao WC, Yang ZY, et al. Research progress on the anti—inflammatory effects of calycosin. Chin Tradit Herb Drugs. 2025; 56(6):2238-2248. https://doi.org/CNKI:SUN:ZCYO.0.2025—06—032.

[4] Dai YT, Zhang XY, Wang YX, et al. Modern research progress of Astragalus membranaceus and predictive analysis of its quality markers. China J Chin Mater Med. 2022; 47(7):1754-1764. https://doi.org/10.19540/j.cnki.cjcmm.20211213.201.

[5] Zhang Y, Chen Z, Chen L, et al. Astragali Radix (Huangqi): a time—honored nourishing herbal medicine. Chin Med. 2024; 19(1):119. https://doi.org/10.1186/s13020—024—00977—z.

[6] Ye J, Huang Y, Jiang X, et al. Research on the interaction of astragaloside IV and calycosin in Astragalus membranaceus with HMGB1. Chin Med. 2023; 18(1):81. https://doi.org/10.1186/s13020—023—00789—7.

[7] Chang Y, Li Z, Wang M, et al. Calycosin inhibits porcine reproductive and respiratory syndrome virus replication and activates RIG—I/IRF3 signaling pathway. Front Vet Sci. 2025; 12:1674259.

[8] Lu XQ, Qin S, Li J. Radical scavenging capability and mechanism of three isoflavonoids extracted from Radix Astragali: a theoretical study. Molecules. 2023; 28(13):5039. https://doi.org/10.3390/molecules28135039.

[9] Wang XZ, Zhang XY, Mou Y, et al. Research progress on the antitumor effects and mechanisms of calycosin. Chin J Exp Tradit Med Form. 2021; 27(23):210-217. https://doi.org/10.13422/j.cnki.syfjx.20212321.

[10] Cui W, Yang L, Zhang L, et al. Rapid quantitative analysis of 19 bioactive components in Fangji Huangqi Decoction based on UHPLC—MS/MS. J Chromatogr Sci. 2023; 61(9):852-862. https://doi.org/10.1093/chromsci/bmac085.

[11] Chen YR. Study on the flash extraction process and fingerprint of Astragalus polysaccharides, saponins, flavonoids, Lycium barbarum polysaccharides, and Polygonatum sibiricum polysaccharides. Wuhan: Huazhong University of Science and Technology. 2011.

[12] Pan C, Wang H, Shan H, et al. Preparative isolation and purification of calycosin and formononetin from Astragali Radix using hydrolytic extraction combined with high speed countercurrent chromatography. J Chromatogr Sci. 2021; 59(5):412-418. https://doi.org/10.1093/chromsci/bmab021.

[13] Niu HZ. Extraction, separation, and in vitro activity of isoflavones from legume plants Cicer arietinum and Glycine max. Changchun: Changchun Normal University. 2022. https://doi.org/10.27709/d.cnki.gccsf.2022.000290.

[14] Chen CY. Enrichment, separation, purification, and antioxidant activity of calycosin and formononetin from Astragalus membranaceus. Harbin: Northeast Forestry University. 2012.

[15] Zhang P, Wu N, Song ZJ, et al. Optimization of macroporous resin purification process for calycosin from Astragalus membranaceus by response surface methodology. Sci Technol Food Ind. 2021; 42(10):209-214. https://doi.org/10.13386/j.issn1002—0306.2020110048.

[16] Wang X, Tang SA, Duan HQ. Study on the flavonoid chemical constituents of Astragalus membranaceus. J Tianjin Med Univ. 2016; 22(5):409-411. https://doi.org/10.20135/j.issn.1006—8147.2016.05.012.

[17] Ma XF, Tu PF, Chen YJ, et al. Separation and purification of formononetin and calycosin from Astragalus membranaceus by high—speed counter—current chromatography. Chin J Chromatogr. 2005; 23(3):299-301. https://doi.org/CNKI:SUN:SPZZ.0.2005—03—023.

[18] Zhang YZ, Xu F, Liang J, et al. Study on the isoflavone chemical constituents of Astragalus membranaceus var. mongholicus. Chin J Chin Mater Med. 2012; 37(21):3243-3248. https://doi.org/CNKI:SUN:ZGZY.0.2012—21—021.

[19] Hao Y. Biosynthetic pathway analysis of isoflavonoids in Astragalus membranaceus. Jinan: Shandong University; 2024. https://doi.org/10.27272/d.cnki.gshdu.2024.003872.

[20] Xu XJ. Effects of LED light on the growth of Astragalus membranaceus hairy roots and the biosynthesis of formononetin and calycosin. Harbin: Northeast Forestry University. 2022. https://doi.org/10.27009/d.cnki.gdblu.2022.001133.

[21] Jin HY, Yu Y, Quan XL, Wu SQ. Promising strategy for improving calycosin—7—O—β—D—glucoside production in Astragalus membranaceus adventitious root cultures. Ind Crops Prod. 2019; 141:111792. https://doi.org/10.1016/j.indcrop.2019.111792.

[22] Gai QY, Jiao J, Wang X, et al. Chitosan promoting formononetin and calycosin accumulation in Astragalus membranaceus hairy root cultures via mitogen—activated protein kinase signaling cascades. Sci Rep. 2019; 9(1):10367. https://doi.org/10.1038/s41598—019—46820—6.

[23] Fu XW, Wang X, Pu WC, et al. Synthesis and antitumor activity of calycosin and its derivatives. Chin J Synth Chem. 2015; 23(3):223-226. https://doi.org/10.15952/j.cnki.cjsc.1005—1511.2015.03.0223.

[24] Hu Y, Min J, Qu Y, et al. Biocatalytic synthesis of calycosin—7—O—β—D—glucoside with uridine diphosphate—glucose regeneration system. Catalysts. 2020; 10(2):258. https://doi.org/10.3390/catal10020258.

[25] Yang FH. Synthesis of calycosin derivatives and their anti—ovarian cancer activity. Guilin: Guilin Medical University. 2023. https://doi.org/10.27806/d.cnki.gglyx.2023.000109.

[26] Yin F, Zhang X, Li Y, et al. In silico analysis reveals the core targets and mechanisms of CA028, a new derivative of calycosin, in the treatment of colorectal cancer. Intell Med. 2022; 2(3):127-133. https://doi.org/10.1016/j.imed.2022.03.002.

[27] Wei W. Study on the anti—breast cancer activity of calycosin derivative H10. Guilin: Guilin Medical University. 2023. https://doi.org/10.27806/d.cnki.gglyx.2023.000072.

[28] Alaaeldin R, Eisa YA, El—Rehany MA, Fathy M. Vincamine alleviates intrahepatic cholestasis in rats through modulation of NF—κB/PDGF/KLF6/PPARγ and PI3K/Akt pathways. Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7981-7994. https://doi.org/10.1007/s00210—024—03119—2.

[29] Lawrence BD, Infanger DW. Effect of silk fibroin protein hydrolysis on biochemistry, gelation kinetics, and NF—κB bioactivity in vitro. Int J Biol Macromol. 2024; 272(Pt 1):132702. https://doi.org/10.1016/j.ijbiomac.2024.132702.

[30] Zhang L, He J, Zhao W, et al. CD2AP promotes the progression of glioblastoma multiforme via TRIM5—mediated NF—κB signaling. Cell Death Dis. 2024; 15(10):722. https://doi.org/10.1038/s41419—024—07094—7.

[31] Liu F, Zhao Y, Pei Y, Lian F, Lin H. Role of the NF—κB signalling pathway in heterotopic ossification: biological and therapeutic significance. Cell Commun Signal. 2024; 22(1):159. https://doi.org/10.1186/s12964—024—01533—w.

[32] Chao L, Zheng P, Xia L, et al. Calycosin attenuates dextran sulfate sodium (DSS)—induced experimental colitis. Iran J Basic Med Sci. 2017; 20(9):1056-1062. https://doi.org/10.22038/IJBMS.2017.9276.

[33] Dong L, Yin L, Chen R, et al. Anti—inflammatory effect of calycosin glycoside on lipopolysaccharide—induced inflammatory responses in RAW 264.7 cells. Gene. 2018; 675:94-101. https://doi.org/10.1016/j.gene.2018.06.057.

[34] Tao Y, Wang Y, Wang X, et al. Calycosin suppresses epithelial derived initiative key factors and maintains epithelial barrier in allergic inflammation via TLR4—mediated NF—κB pathway. Cell Physiol Biochem. 2017; 44(3):1106-1119. https://doi.org/10.1159/000485416.

[35] Fortson BL, Abu—El—Haija M, Mahalingam N, et al. Pancreas volumes in pediatric patients following index acute pancreatitis and acute recurrent pancreatitis. Pancreatology. 2024; 24(1):1-5. https://doi.org/10.1016/j.pan.2023.10.025.

[36] Ma R, Yuan F, Wang S, et al. Calycosin alleviates cerulein—induced acute pancreatitis by inhibiting the inflammatory response and oxidative stress via the p38 MAPK and NF—κB signal pathways in mice. Biomed Pharmacother. 2018; 105:599-605. https://doi.org/10.1016/j.biopha.2018.05.080.

[37] Herdiana Y, Wardhana YW, Kurniawansyah IS, et al. Current status of gout arthritis: current approaches to gout arthritis treatment: nanoparticles delivery systems approach. Pharmaceutics. 2025; 17(1):102. https://doi.org/10.3390/pharmaceutics17010102.

[38] Tian J, Zhou D, Xiang L, et al. Calycosin represses AIM2 inflammasome—mediated inflammation and pyroptosis to attenuate monosodium urate—induced gouty arthritis through NF—κB and p62—Keap1 pathways. Drug Dev Res. 2022; 83(7):1654-1672. https://doi.org/10.1002/ddr.21985.

[39] Wu LL, Shi WD, Peng WF, Li GY. Unraveling the interplay between meningitis and mitochondria: etiology, pathogenesis, and therapeutic insights. Int Immunopharmacol. 2025; 147:113985. https://doi.org/10.1016/j.intimp.2024.113985.

[40] Lu CY, Chen KM, Kuo WW, et al. Calycosin attenuates Angiostrongylus cantonensis—induced parasitic meningitis through modulation of HO—1 and NF—κB activation. Parasitology. 2023; 150(4):311-320. https://doi.org/10.1017/S0031182022001408.

[41] Hu H, Ding G, Liang W. Dietary therapy to halt the progression of diabetes to diabetic kidney disease. Food Funct. 2025; 16(7):2622-2636. https://doi.org/10.1039/d4fo06011c.

[42] Zhang YY, Tan RZ, Zhang XQ, et al. Calycosin ameliorates diabetes—induced renal inflammation via the NF—κB pathway in vitro and in vivo. Med Sci Monit. 2019; 25:1671-1678. https://doi.org/10.12659/MSM.915242.

[43] Zhu CJ, Yang WG, Li DJ, et al. Calycosin attenuates severe acute pancreatitis—associated acute lung injury by curtailing high mobility group box 1—induced inflammation. World J Gastroenterol. 2021; 27(44):7669-7686. https://doi.org/10.3748/wjg.v27.i44.7669.

[44] Sahu M, Jain U. Activation, interaction and intimation of Nrf2 pathway and their mutational studies causing Nrf2 associated cancer. Biochim Biophys Acta Mol Basis Dis. 2025; 1871(5):167764. https://doi.org/10.1016/j.bbadis.2025.167764.

[45] Chen C, Cui J, Ji X, et al. Neuroprotective functions of calycosin against intracerebral hemorrhage—induced oxidative stress and neuroinflammation. Future Med Chem. 2020; 12(7):583-592. https://doi.org/10.4155/fmc—2019—0311.

[46] Liu Y, Piao XJ, Xu WT, et al. Calycosin induces mitochondrial—dependent apoptosis and cell cycle arrest, and inhibits cell migration through a ROS—mediated signaling pathway in HepG2 hepatocellular carcinoma cells. Toxicol In Vitro. 2021; 70:105052. https://doi.org/10.1016/j.tiv.2020.105052.

[47] Qiu R, Li X, Qin K, et al. Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism. Biofactors. 2019; 45(6):975-982. https://doi.org/10.1002/biof.1545.

[48] Qiu R, Ma G, Li X, et al. Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells. J Cell Biochem. 2019; 120(6):10697-10706. https://doi.org/10.1002/jcb.28360.

[49] Morimoto A, Takasugi N, Pan Y, et al. Methyl vinyl ketone and its analogs covalently modify PI3K and alter physiological functions by inhibiting PI3K signaling. J Biol Chem. 2024; 300(3):105679. https://doi.org/10.1016/j.jbc.2024.105679.

[50] Abdelilah—Seyfried S, Ola R. Shear stress and pathophysiological PI3K involvement in vascular malformations. J Clin Invest. 2024; 134(10):e172843. https://doi.org/10.1172/JCI172843.

[51] Pan J, Yao Q, Wang Y, et al. The role of PI3K signaling pathway in Alzheimer’s disease. Front Aging Neurosci. 2024; 16:1459025. https://doi.org/10.3389/fnagi.2024.1459025.

[52] Blaustein M, Piegari E, Martínez Calejman C, et al. Akt is S—palmitoylated: a new layer of regulation for Akt. Front Cell Dev Biol. 2021; 9:626404. https://doi.org/10.3389/fcell.2021.626404.

[53] Harris JW, de Oliveira Simões FA, Ryerson EN, et al. Live—cell NanoBRET assay to measure AKT inhibitor binding to conformational states of AKT. ACS Chem Biol. 2025; 20(7):1635-1645. https://doi.org/10.1021/acschembio.5c00213.

[54] Zhu L, Liu S, Liao YF, et al. Calycosin suppresses colorectal cancer progression by targeting ERβ, upregulating PTEN, and inhibiting PI3K/Akt signal pathway. Cell Biol Int. 2022; 46(9):1367-1377. https://doi.org/10.1002/cbin.11840.

[55] Sun H, Yin M, Qian W, et al. Calycosin, a phytoestrogen isoflavone, induces apoptosis of estrogen receptor—positive MG—63 osteosarcoma cells via the phosphatidylinositol 3—kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Med Sci Monit. 2018; 24:6178-6186. https://doi.org/10.12659/MSM.910201.

[56] Nie X, Zhou Y, Li X, et al. Calycosin down—regulates c—Met to suppress development of glioblastomas. J Biosci. 2019; 44(4):96. https://doi.org/10.1007/s12038—019—9904—4.

[57] Wang Q, Lu W, Yin T, Lu L. Correction to: calycosin suppresses TGF—β—induced epithelial—to—mesenchymal transition and migration by upregulating BATF2 to target PAI—1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells. Exp Clin Cancer Res. 2019; 38(1):288. https://doi.org/10.1186/s13046—019—1298—5.

[58] Liu X, Shao Y, Zhang X, et al. Calycosin attenuates pulmonary fibrosis by the epithelial—mesenchymal transition repression upon inhibiting the AKT/GSK3β/β—catenin signaling pathway. Acta Histochem. 2021; 123(5):151746. https://doi.org/10.1016/j.acthis.2021.151746.

[59] Lu CY, Day CH, Kuo CH, et al. Calycosin alleviates H₂O₂—induced astrocyte injury by restricting oxidative stress through the Akt/Nrf2/HO—1 signaling pathway. Environ Toxicol. 2022; 37(4):858-867. https://doi.org/10.1002/tox.23449.

[60] Li M, Huan Y, Jiang T, et al. Rehabilitation training enhanced the therapeutic effect of calycosin on neurological function recovery of rats following spinal cord injury. J Chem Neuroanat. 2024; 136:102384. https://doi.org/10.1016/j.jchemneu.2023.102384.

[61] Guo X, Pan X, Wu J, et al. Calycosin prevents IL—1β—induced articular chondrocyte damage in osteoarthritis through regulating the PI3K/AKT/FoxO1 pathway. In Vitro Cell Dev Biol Anim. 2022; 58(6):491-502. https://doi.org/10.1007/s11626—022—00694—7.

[62] Cao M, Day AM, Galler M, et al. A peroxiredoxin—P38 MAPK scaffold increases MAPK activity by MAP3K—independent mechanisms. Mol Cell. 2023; 83(17):3140-3154.e7. https://doi.org/10.1016/j.molcel.2023.07.018.

[63] Kciuk M, Gielecińska A, Budzinska A, et al. Metastasis and MAPK pathways. Int J Mol Sci. 2022; 23(7):3847. https://doi.org/10.3390/ijms23073847.

[64] Usta D, Sigaud R, Buhl JL, et al. A cell—based MAPK reporter assay reveals synergistic MAPK pathway activity suppression by MAPK inhibitor combination in BRAF—driven pediatric low—grade glioma cells. Mol Cancer Ther. 2020; 19(8):1736-1750. https://doi.org/10.1158/1535—7163.MCT—19—1021.

[65] Ayatollahi Z, Kazanaviciute V, Shubchynskyy V, et al. Dual control of MAPK activities by AP2C1 and MKP1 MAPK phosphatases regulates defence responses in Arabidopsis. J Exp Bot. 2022; 73(8):2369-2384. https://doi.org/10.1093/jxb/erac018.

[66] Ma H, Chen J, Zhang Z, et al. MAPK kinase 10.2 promotes disease resistance and drought tolerance by activating different MAPKs in rice. Plant J. 2017; 92(4):557-570. https://doi.org/10.1111/tpj.13674.

[67] Li M, Cui L, Feng X, et al. Losmapimod protected epileptic rats from hippocampal neuron damage through inhibition of the MAPK pathway. Front Pharmacol. 2019; 10:625. https://doi.org/10.3389/fphar.2019.00625.

[68] Chen X, Lv Q, Ma J, Liu Y. PLCγ2 promotes apoptosis while inhibits proliferation in rat hepatocytes through PKCD/JNK MAPK and PKCD/p38 MAPK signalling. Cell Prolif. 2018; 51(3):e12437. https://doi.org/10.1111/cpr.12437.

[69] Ye G, Lin C, Zhang Y, et al. Quercetin alleviates neuropathic pain in the rat CCI model by mediating AMPK/MAPK pathway. J Pain Res. 2021; 14:1289-1301. https://doi.org/10.2147/JPR.S298727.

[70] Wang C, Zhang S, Huang L, et al. Chemerin promotes MAPK/ERK activation to induce inflammatory factor production in rat synoviocytes. Exp Ther Med. 2022; 24(5):684. https://doi.org/10.3892/etm.2022.11620.

[71] You S, Wang Y, Guo Y, et al. Activation of the ERK1/2 pathway mediates the neuroprotective effect provided by calycosin treatment. Neurosci Lett. 2023; 792:136956. https://doi.org/10.1016/j.neulet.2022.136956.

[72] Hu Y, Zhai W, Tan D, et al. Uncovering the effects and molecular mechanism of Astragalus membranaceus (Fisch.) Bunge and its bioactive ingredients formononetin and calycosin against colon cancer: an integrated approach based on network pharmacology analysis coupled with experimental validation and molecular docking. Front Pharmacol. 2023; 14:1111912. https://doi.org/10.3389/fphar.2023.1111912.

[73] Tian W, Wang ZW, Yuan BM, et al. Calycosin induces apoptosis via p38—MAPK pathway—mediated activation of the mitochondrial apoptotic pathway in human osteosarcoma 143B cells. Mol Med Rep. 2020; 22(5):3962-3968. https://doi.org/10.3892/mmr.2020.11471.

[74] Liu F, Pan Q, Wang L, et al. Anticancer targets and mechanisms of calycosin to treat nasopharyngeal carcinoma. Biofactors. 2020; 46(4):675-684. https://doi.org/10.1002/biof.1639.

[75] Zhang Z, Auyeung KK, Sze SC, et al. The dual roles of calycosin in growth inhibition and metastatic progression during pancreatic cancer development: a “TGF—β paradox”. Phytomedicine. 2020; 68:153177. https://doi.org/10.1016/j.phymed.2020.153177.

[76] Ding X, Lv J, Luan J, et al. Calycosin may alleviate Ang II—induced pro—proliferative effects on glomerular mesangial cells by partially inhibiting autophagy and ERK signaling pathway. Biol Pharm Bull. 2020; 43(12):1893-1898. https://doi.org/10.1248/bpb.b20—00520.

[77] Ji X, Hu Q, Yang C, et al. Exploring the therapeutic effect of Pen Yan Kang Fu Decoction on SPID rats based on LIF/JAK2/STAT3 signaling pathway. AMB Express. 2024; 14(5):134. https://doi.org/10.1007/s13205—024—03981—0.

[78] Ciftel S, Mercantepe F, Mercantepe T, et al. Dexmedetomidine on the interplay of IL—6 and STAT3 pathways in adrenal gland damage—induced scalding burns in rats. Naunyn Schmiedebergs Arch Pharmacol. 2025; 398(1):641-655. https://doi.org/10.1007/s00210—024—03300—7.

[79] Gan L, Geng L, Li Q, et al. Allicin ameliorated high—glucose peritoneal dialysis solution—induced peritoneal fibrosis in rats via the JAK2/STAT3 signaling pathway. Cell Biochem Biophys. 2025; 83(2):1847-1859. https://doi.org/10.1007/s12013—024—01593—2.

[80] Wang S, Taledaohan A, Tuohan M, et al. Jinmaitong alleviates diabetic neuropathic pain by inhibiting JAK2/STAT3 signaling in microglia of diabetic rats. J Ethnopharmacol. 2024; 333:118442. https://doi.org/10.1016/j.jep.2024.118442.

[81] Xiao S, Zhang Y, Wang S, et al. The SYVN1 inhibits neuronal cell ferroptosis by activating STAT3/GPX4 axis in rat with spinal cord injury. Cell Prolif. 2024; 57(10):e13658. https://doi.org/10.1111/cpr.13658.

[82] Xu S, Huang P, Yang J, et al. Calycosin alleviates cerebral ischemia/reperfusion injury by repressing autophagy via STAT3/FOXO3a signaling pathway.Phytomedicine. 2023; 115:154845. https://doi.org/10.1016/j.phymed.2023.154845.

[83] Liu Y, Che G, Di Z, et al. Calycosin—7—O—β—D—glucoside attenuates myocardial ischemia—reperfusion injury by activating JAK2/STAT3 signaling pathway via the regulation of IL—10 secretion in mice. Mol Cell Biochem. 2020; 463(1—2):175-187. https://doi.org/10.1007/s11010—019—03639—z.

[84] Song Y, Li X, Liu X, et al. Calycosin alleviates oxidative injury in spinal astrocytes by regulating the GP130/JAK/STAT pathway. J Oleo Sci. 2022; 71(6):881-887. https://doi.org/10.5650/jos.ess21174.

[85] Wang Y, Wu C, Zhou J, et al. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti—fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC Pharmacol Toxicol. 2022; 23(1):77. https://doi.org/10.1186/s40360—022—00617—y.

[86] Li D, Zhao L, Li Y, et al. Gastro—protective effects of calycosin against precancerous lesions of gastric carcinoma in rats. Drug Des Devel Ther. 2020; 14:2207-2219. https://doi.org/10.2147/DDDT.S247958.

[87] Yan WJ, Wang DB, Ren DQ, et al. AMPKα1 overexpression improves postoperative cognitive dysfunction in aged rats through AMPK—Sirt1 and autophagy signaling. J Cell Biochem. 2019; 120(7):11633-11641. https://doi.org/10.1002/jcb.28443.

[88] Zhang X, Ren X, Sun W, et al. PFOA exposure induces aberrant glucose and lipid metabolism in the rat liver through the AMPK/mTOR pathway. Toxicology. 2023; 493:153551. https://doi.org/10.1016/j.tox.2023.153551.

[89] Zhao JJ, Zhao B, Bai X, et al. Aucubin promotes activation of AMPK and alleviates cerebral ischemia/reperfusion injury in rats. Cell Stress Chaperones. 2023; 28(6):801-809. https://doi.org/10.1007/s12192—023—01372—7.

[90] Tu Y, Gu L, Chen D, et al. Rhein inhibits autophagy in rat renal tubular cells by regulation of AMPK/mTOR signaling. Sci Rep. 2017; 7:43790. https://doi.org/10.1038/srep43790.

[91] Mohammed HM. Zingerone ameliorates non—alcoholic fatty liver disease in rats by activating AMPK. J Food Biochem. 2022; 46(7):e14149. https://doi.org/10.1111/jfbc.14149.

[92] Zhou Z, Li Y, Jiang W, et al. Molecular mechanism of calycosin inhibited vascular calcification. Nutrients. 2023; 16(1):99. https://doi.org/10.3390/nu16010099.

[93] Li S, Qian R, Xie W, et al. AMPK regulates the anti—pulmonary fibrosis effects of tracheloside. Chin J Nat Med. 2025; 23(12):100005. https://doi.org/10.1016/j.cjnm.2025.100005.

[94] Gong AGW, Duan R, Wang HY, et al. Calycosin orchestrates osteogenesis of Danggui Buxue Tang in cultured osteoblasts: evaluating the mechanism of action by omics and chemical knock—out methodologies. Front Pharmacol. 2018; 9:36. https://doi.org/10.3389/fphar.2018.00036.

[95] Hu R, Wang MQ, Liu LY, et al. Calycosin inhibited autophagy and oxidative stress in chronic kidney disease skeletal muscle atrophy by regulating AMPK/SKP2/CARM1 signalling pathway. J Cell Mol Med. 2020; 24(19):11084-11099. https://doi.org/10.1111/jcmm.15514.

[96] Han F, Li K, Pan R, et al. Calycosin directly improves perivascular adipose tissue dysfunction by upregulating the adiponectin/AMPK/eNOS pathway in obese mice. Food Funct. 2018; 9(4):2409-2415. https://doi.org/10.1039/c8fo00328a.

[97] Peng D, Fu M, Wang M, et al. Targeting TGF—β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022; 21(1):104. https://doi.org/10.1186/s12943—022—01569—x.

[98] Aashaq S, Batool A, Mir SA, et al. TGF—β signaling: a recap of SMAD—independent and SMAD—dependent pathways. J Cell Physiol. 2022; 237(1):59-85. https://doi.org/10.1002/jcp.30529.

[99] Wu M, Wu S, Chen W, et al. The roles and regulatory mechanisms of TGF—β and BMP signaling in bone and cartilage development, homeostasis and disease. Cell Res. 2024; 34(2):101-123. https://doi.org/10.1038/s41422—023—00918—9.

[100] Lan XQ, Deng CJ, Wang QQ, et al. The role of TGF—β signaling in muscle atrophy, sarcopenia and cancer cachexia. Gen Comp Endocrinol. 2024; 353:114513. https://doi.org/10.1016/j.ygcen.2024.114513.

[101] Zhang Z, Lin M, Wang J, et al. Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT via BATF/TGF—β1. Aging (Albany NY). 2021; 13(12):16009-16023. https://doi.org/10.18632/aging.203093.

[102] Liu J, Deng T, Wang Y, et al. Calycosin inhibits intestinal fibrosis on CCD—18Co cells via modulating transforming growth factor—β/Smad signaling pathway.Pharmacology. 2019; 104(1—2):81-89. https://doi.org/10.1159/000500186.

[103] Chen G, Xu H, Xu T, et al. Calycosin reduces myocardial fibrosis and improves cardiac function in post—myocardial infarction mice by suppressing TGFBR1 signaling pathways. Phytomedicine. 2022; 104:154277. https://doi.org/10.1016/j.phymed.2022.154277.

[104] Hu Q, Zhu B, Yang G, et al. Calycosin pretreatment enhanced the therapeutic efficacy of mesenchymal stem cells to alleviate unilateral ureteral obstruction—induced renal fibrosis by inhibiting necroptosis. J Pharmacol Sci. 2023; 151(2):72-83. https://doi.org/10.1016/j.jphs.2022.12.001.

[105] Vande Walle L, Lamkanfi M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2024; 23(1):43-66. https://doi.org/10.1038/s41573—023—00822—2.

[106] Kodi T, Sankhe R, Gopinathan A, et al. New insights on NLRP3 inflammasome: mechanisms of activation, inhibition, and epigenetic regulation. J Neuroimmune Pharmacol. 2024; 19(1):7. https://doi.org/10.1007/s11481—024—10101—5.

[107] Ren W, Sun Y, Zhao L, et al. NLRP3 inflammasome and its role in autoimmune diseases: a promising therapeutic target. Biomed Pharmacother. 2024; 175:116679. https://doi.org/10.1016/j.biopha.2024.116679.

[108] Hashim N, Babiker R, Mohammed R, et al. NLRP3 inflammasome in autoinflammatory diseases and periodontitis advance in the management. J Pharm Bioallied Sci. 2024; 16(Suppl 2):S1110-S1119. https://doi.org/10.4103/jpbs.jpbs_1118_23.

[109] Jin J, Zhang M. Exploring the role of NLRP3 inflammasome in diabetic nephropathy and the advancements in herbal therapeutics. Front Endocrinol. 2024; 15:1397301. https://doi.org/10.3389/fendo.2024.1397301.

[110] Yosri H, El—Kashef DH, El—Sherbiny M, et al. Calycosin modulates NLRP3 and TXNIP—mediated pyroptotic signaling and attenuates diabetic nephropathy progression in diabetic rats: an insight. Biomed Pharmacother. 2022; 155:113758. https://doi.org/10.1016/j.biopha.2022.113758.

[111] Zhang L, Fan C, Jiao HC, et al. Calycosin alleviates doxorubicin—induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation. Oxid Med Cell Longev. 2022; 2022:1733834. https://doi.org/10.1155/2022/1733834.

[112] Xia Y, Cao Y, Sun Y, et al. Calycosin alleviates sepsis—induced acute lung injury by the inhibition of mitochondrial ROS—mediated inflammasome activation. Front Pharmacol. 2021; 12:690549. https://doi.org/10.3389/fphar.2021.690549.

[113] Zhang Q, Yang C, Ma S, et al. Shiwei Qingwen decoction regulates TLR4/NF—κB signaling pathway and NLRP3 inflammasome to reduce inflammatory response in lipopolysaccharide—induced acute lung injury. J Ethnopharmacol. 2023; 313:116615. https://doi.org/10.1016/j.jep.2023.116615.

[114] Yuan Y, Liu H, Meng Q. The cardioprotective effects and mechanisms of Astragalus—safflower herb pairs on coronary heart disease identified by network pharmacology and experimental verification. Front Biosci. 2023; 28(5):94. https://doi.org/10.31083/j.fbl2805094.

[115] Borgeaud M, Parikh K, Banna GL, et al. Unveiling the landscape of uncommon EGFR mutations in NSCLC: a systematic review. J Thorac Oncol. 2024; 19(7):973-983. https://doi.org/10.1016/j.jtho.2024.03.016.

[116] Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR—mutated non—small cell lung cancer. Br J Cancer. 2019; 121(9):725-737. https://doi.org/10.1038/s41416—019—0573—8.

[117] Zhou J, Ji Q, Li Q. Resistance to anti—EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Exp Clin Cancer Res. 2021; 40(1):328. https://doi.org/10.1186/s13046—021—02130—2.

[118] Liang K, Ta Y, Xu L, et al. Trans—sodium crocetinate ameliorates high—altitude acute lung injury via modulating EGFR/PI3K/AKT/NF—κB signaling axis.Nutrients. 2025; 17(15):2406. https://doi.org/10.3390/nu17152406.

[119] Su H, Yan Q, Du W, et al. Calycosin ameliorates osteoarthritis by regulating the imbalance between chondrocyte synthesis and catabolism. BMC Complement Med Ther. 2024; 24(1):48. https://doi.org/10.1186/s12906—023—04314—z.

[120] Liu Q, Zhang J, Han X, et al. Huiyang Shengji Decoction promotes wound healing in diabetic mice by activating the EGFR/PI3K/ATK pathway. Chin Med. 2021; 16(1):111. https://doi.org/10.1186/s13020—021—00497—0.

[121] Maimaitiaili N, Zeng Y, Ju P, et al. NLRC3 deficiency promotes hypoxia—induced pulmonary hypertension development via IKK/NF—κB p65/HIF—1α pathway. Exp Cell Res. 2023; 431(2):113755. https://doi.org/10.1016/j.yexcr.2023.113755.

[122] Xiao Z, Jiang S, Fu S, et al. Unveiling the therapeutic mechanism of Epimedium Herba on prostate cancer through network pharmacology and experimental validation. Chin J Nat Med. 2025; 23(12):100016. https://doi.org/10.1016/j.cjnm.2025.100016.

[123] Shen Z, Yu N, Zhang Y, et al. The potential roles of HIF—1α in epithelial—mesenchymal transition and ferroptosis in tumor cells. Cell Signal. 2024; 122:111345. https://doi.org/10.1016/j.cellsig.2024.111345.

[124] Zhu T, Wang B, Huang W, et al. Anti—inflammatory effect of calycosin on hypoxia—induced retinal pigment epithelium cells. Discov Med. 2025; 37(194):525-534. https://doi.org/10.24976/Discov.Med.202537194.44.

[125] Zhang YM, Miao ZM, Chen YP, et al. Ononin promotes radiosensitivity in lung cancer by inhibiting HIF—1α/VEGF pathway. Phytomedicine. 2024; 125:155290. https://doi.org/10.1016/j.phymed.2023.155290.

[126] Zheng ZX, Liu EY, Wu QY, et al. The flavonoids induce the transcription of mRNA encoding erythropoietin in cultured embryonic stem cells via the accumulation of hypoxia—inducible factor—1α. Chem Biol Interact. 2023; 382:110609. https://doi.org/10.1016/j.cbi.2023.110609.

[127] Zheng KY, Choi RC, Cheung AW, et al. Flavonoids from Radix Astragali induce the expression of erythropoietin in cultured cells: a signaling mediated via the accumulation of hypoxia—inducible factor—1α. J Agric Food Chem. 2011; 59(5):1697-1704. https://doi.org/10.1021/jf104018u.

[128] Jia Z, Wang X, Wang X, et al. Calycosin alleviates allergic contact dermatitis by repairing epithelial tight junctions via down—regulating HIF—1α. J Cell Mol Med. 2018; 22(9):4507-4521. https://doi.org/10.1111/jcmm.13763.

[129] Ding C, Wu Y, Zhan C, et al. Research progress on the role and inhibitors of Keap1 signaling pathway in inflammation. Int Immunopharmacol. 2024; 141:112853. https://doi.org/10.1016/j.intimp.2024.112853.

[130] Huang Y, Zhang X, Chen L, et al. Lycium barbarum ameliorates neural damage induced by experimental ischemic stroke and radiation exposure. Front Biosci (Landmark Ed). 2023; 28(2):38. https://doi.org/10.31083/j.fbl2802038.

[131] Zhang Q, Liu J, Duan H, et al. Activation of Nrf2/HO—1 signaling: an important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress.J Adv Res. 2021; 34:43-63. https://doi.org/10.1016/j.jare.2021.06.023.

[132] Liu H, Bai X, Wei W, et al. Calycosin ameliorates bleomycin—induced pulmonary fibrosis by suppressing oxidative stress, apoptosis, and enhancing autophagy. Evid Based Complement Alternat Med. 2022; 2022:9969729. https://doi.org/10.1155/2022/9969729.

[133] Ma Q, Yu J, Zhang X, et al. Wnt/β—catenin signaling pathway: a versatile player in apoptosis and autophagy. Biochimie. 2023; 211:57-67. https://doi.org/10.1016/j.biochi.2023.03.001.

[134] Song J, Yang JP, Yang JK, et al. Wnt/GSK3β/β—catenin signaling pathway regulates calycosin—mediated anticancer effects in glioblastoma multiforme cells. Arab J Chem. 2023; 16(5):104567. https://doi.org/10.1016/j.arabjc.2023.104567.

[135] Shakerian L, Kolahdooz H, Garousi M, et al. IL—33/ST2 axis in autoimmune disease. Cytokine. 2022; 158:156015. https://doi.org/10.1016/j.cyto.2022.156015.

[136] Elsherbiny NM, Said E, Atef H, et al. Renoprotective effect of calycosin in high fat diet—fed/STZ injected rats: effect on IL—33/ST2 signaling, oxidative stress and fibrosis suppression. Chem Biol Interact. 2020; 315:108897. https://doi.org/10.1016/j.cbi.2019.108897.

[137] Guan J, Wang L, Ji Y, et al. UHPLC—MS/MS method for quantifying Fangchinoline, Tetrandrine and Calycosin—7—O—β—D—glucoside of Fangji Huangqi decoction in rat plasma and its application to a pharmacokinetic study. J Chromatogr Sci. 2022; 60(5):458-464. https://doi.org/10.1093/chromsci/bmab116.

[138] Wen XD, Qi LW, Li B, et al. Microsomal metabolism of calycosin, formononetin and drug—drug interactions by dynamic microdialysis sampling and HPLC—DAD—MS analysis. J Pharm Biomed Anal. 2009; 50(1):100-105. https://doi.org/10.1016/j.jpba.2009.03.038.

[139] Gu Y, Piao X, Zhu D. Simultaneous determination of calycosin, prim—O—glucosylcimifugin, and paeoniflorin in rat plasma by HPLC—MS/MS: application in the pharmacokinetic analysis of HQCF. J Int Med Res. 2020; 48(11):300060520972902. https://doi.org/10.1177/0300060520972902.

[140] Zhao J, Ren Y, Qu Y, et al. Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis. Sci Rep. 2017; 7(1):3458. https://doi.org/10.1038/s41598—017—02774—1.

[141] Zhou L. Study on the absorption and metabolic characteristics of the active ingredient calycosin from Astragalus membranaceus. Nanjing: Nanjing University of Chinese Medicine; 2014.

[142] Tian X, Chen S, Zhang Y, et al. Absorption, liver first—pass effect, pharmacokinetics and tissue distribution of calycosin—7—O—β—D—glucopyranoside (C7G) and its major active metabolite, calycosin, following oral administration of C7G in rats by LC—MS/MS. J Pharm Biomed Anal. 2018; 148:350-354. https://doi.org/10.1016/j.jpba.2017.10.027.

[143] Liu XH, Zhu RJ, Hu F, et al. Tissue distribution of six major bio—active components after oral administration of Zhenqi Fuzheng Capsules to rats using ultra—pressure liquid chromatography—tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 986—987:44-53. https://doi.org/10.1016/j.jchromb.2015.01.033.

[144] He M, Chen W, Wang M, et al. Simultaneous determination of multiple bioactive components of Bu—zhong—yi—qi—tang in rat tissues by LC—MS/MS: application to a tissue distribution study. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1044—1045:177-184. https://doi.org/10.1016/j.jchromb.2017.01.023.

[145] Chen Q, Wan J, Zhang Y, et al. Pharmacokinetic—pharmacodynamic modeling analysis for hydroxysafflor yellow A—calycosin in compatibility in normal and cerebral ischemic rats: a comparative study. Biomed Pharmacother. 2022; 150:112950. https://doi.org/10.1016/j.biopha.2022.112950.

[146] Yu J, Zhu L, Zheng H, et al. Sulfotransferases and breast cancer resistance protein determine the disposition of calycosinin vitro and in vivo. Mol Pharm. 2017; 14(9):2917-2929. https://doi.org/10.1021/acs.molpharmaceut.7b00042.

[147] Yun WJ, Yao ZH, Fan CL, et al. Systematic screening and characterization of Qi—Li—Qiang—Xin capsule—related xenobiotics in rats by ultra—performance liquid chromatography coupled with quadrupole time—of—flight tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018; 1090:56-64. https://doi.org/10.1016/j.jchromb.2018.05.014.

[148] Chen SJ. Study on the in vivo process of calycosin—7—O—β—D—glucopyranoside and its aglycone in rats. Shanghai: Shanghai Normal University. 2018.

[149] Shi J, Zheng L, Lin Z, et al. Study of pharmacokinetic profiles and characteristics of active components and their metabolites in rat plasma following oral administration of the water extract of Astragali radix using UPLC—MS/MS. J Ethnopharmacol. 2015; 169:183-194. https://doi.org/10.1016/j.jep.2015.04.019.

[150] Yu Y, Sun P. Calycosin alleviates lupus nephritis by activating the Nrf2/HO—1 signaling pathway. Rev Bras Farmacogn. 2023; 33(5):1052-1059. https://doi.org/10.1007/s43450—023—00435—1.

[151] Zhang D, Sun G, Peng L, et al. Calycosin inhibits viability, induces apoptosis, and suppresses invasion of cervical cancer cells by upregulating tumor suppressor miR—375. Arch Biochem Biophys. 2020; 691:108478. https://doi.org/10.1016/j.abb.2020.108478.

[152] An F, Zhao R, Xuan X, et al. Calycosin ameliorates advanced glycation end product—induced neurodegenerative changes in cellular and rat models of diabetes—related Alzheimer’s disease. Chem Biol Interact. 2022; 368:110206. https://doi.org/10.1016/j.cbi.2022.110206.